Spago Nanomedical has announced positive top line data from a clinical phase IIa study in patients with endometriosis. SPAGOPIX-02 study is evaluating the MRI-enhancing effect of the contrast agent pegfosimer manganese. The data confirms that the primary endpoint was met, without compromising safety.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.36 SEK | 0.00% | +18.42% | +10.09% |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+10.09% | 7.38M | |
-20.55% | 10.82B | |
+47.97% | 3.25B | |
-32.75% | 2.11B | |
-14.15% | 2.08B | |
-26.06% | 1.48B | |
+19.85% | 1.02B | |
-2.62% | 733M | |
-31.67% | 391M | |
-43.88% | 383M |
- Stock Market
- Equities
- SPAGO Stock
- News Spago Nanomedical AB
- Spago Nanomedical Announces Positive Top Line Data from a Clinical Phase IIa Study in Patients with Endometriosis